Skip to main content
    I

    iBio, Inc. Common Stock (IBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.71
    -0.02 (-3.42%)

    Market Cap: $51.55M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    iBio, Inc. Common Stock (IBIO) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect iBio, Inc. Common Stock (IBIO) to earn -$0.27 per share in the fiscal year ending Jun 30, 2027, on revenue of $20000. Of 9 analysts, 9 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Jun 30, 2027 was revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 1.89, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy111.1%
    Buy888.9%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    9

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Jun 30, 2027
    -$0.27
    EPS consensus, revenue $20000
    Fiscal year ending Jun 30, 2028
    -$0.59
    EPS consensus
    Next report
    Feb 8, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Jun 30, 2027-$0.27-$0.40 to -$0.228$20000N/A5
    Jun 30, 2028-$0.59-$1.00 to -$0.265N/AN/A4

    Quarterly Estimates

    Across the 3 quarters below, the EPS consensus is lowest for the quarter ending Jun 30, 2027, at -$0.09, and highest for the quarter ending Dec 31, 2026, at -$0.06.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.06-$0.07 to -$0.053$16670N/A6
    Mar 31, 2027-$0.07-$0.10 to -$0.067N/AN/A6
    Jun 30, 2027-$0.09-$0.13 to -$0.059N/AN/A8

    Estimate Revisions

    Across the 4 periods below, the last 30 days brought 4 upward and 5 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Jun 30, 202713
    Fiscal year ending Jun 30, 202831
    Quarter ending Dec 31, 202600
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Jun 30, 2027 has improved from -$0.31.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Jun 30, 2027-$0.27-$0.38-$0.38-$0.40-$0.31N/A
    Fiscal year ending Jun 30, 2028-$0.59-$0.61-$0.61-$0.61-$0.56N/A
    Quarter ending Dec 31, 2026-$0.06-$0.06-$0.07-$0.08-$0.08N/A
    Quarter ending Mar 31, 2027-$0.07-$0.09-$0.09-$0.09-$0.08N/A

    Frequently Asked Questions About IBIO

    What is the IBIO stock forecast?

    Consensus analyst estimates put iBio, Inc. Common Stock's EPS at -$0.27 for the fiscal year ending Jun 30, 2027, on revenue of $20000. The consensus rating from 9 analysts is Buy.

    How do analysts rate IBIO stock?

    Of 9 analysts covering iBio, Inc. Common Stock, 1 rates it Strong Buy, 8 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from IBIO next year?

    For the fiscal year ending Jun 30, 2027, the consensus EPS estimate is -$0.27, with estimates from -$0.40 to -$0.22 from 8 analysts. For the fiscal year ending Jun 30, 2028, the consensus EPS estimate is -$0.59, with estimates from -$1.00 to -$0.26 from 5 analysts.

    What revenue do analysts expect from iBio, Inc. Common Stock next year?

    For the fiscal year ending Jun 30, 2027, the consensus revenue estimate is $20000.

    How many analysts cover IBIO?

    9 analysts rate iBio, Inc. Common Stock stock, and 8 analysts estimate its EPS for the fiscal year ending Jun 30, 2027.